Indication
High-risk (Secondary) Acute Myeloid Leukemia
1 clinical trial
2 products
Clinical trial
A Randomized, Multi-center, Open-label Phase III Bridging Study to Compare Efficacy of Liposomal Cytarabine-Daunorubicin for Injection With Cytarabine and Daunorubicin in Treating Older Patients With High-Risk (Secondary) Acute Myeloid LeukemiaStatus: Not yet recruiting, Estimated PCD: 2026-02-01
Product
7+3